David A. Siegel Arcutis Biotherapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 182,800 shares of ARQT stock, worth $2.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

182,800

Previous 488,600 62.59%

Holding current value

$2.61 Million

Previous $4.54 Million 62.58%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$8.32 - $11.0 $2.54 Million - $3.36 Million	-305,800 Reduced 62.59%	182,800 $1.7 Million
Q2 2024 Aug 14, 2024	BUY	$7.24 - $12.53 $1.14 Million - $1.98 Million	157,700 Added 47.66%	488,600 $4.54 Million
Q1 2024 May 15, 2024	BUY	$3.25 - $11.77 $1.08 Million - $3.89 Million	330,900 New	330,900 $3.28 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $17.14 $1.22 Million - $2.05 Million	-119,600 Reduced 88.2%	16,000 $176,000
Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $899,024 - $1.31 Million	64,400 Added 90.45%	135,600 $2.01 Million
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $1.27 Million - $1.92 Million	71,200 New	71,200 $1.36 Million
Q4 2021 Feb 14, 2022	SELL	$14.98 - $25.5 $414,946 - $706,350	-27,700 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$19.28 - $27.1 $659,376 - $926,820	-34,200 Reduced 55.25%	27,700 $662,000
Q2 2021 Aug 16, 2021	SELL	$24.42 - $34.75 $383,394 - $545,575	-15,700 Reduced 20.23%	61,900 $1.69 Million
Q1 2021 May 17, 2021	BUY	$24.47 - $36.98 $1.18 Million - $1.79 Million	48,300 Added 164.85%	77,600 $2.25 Million
Q4 2020 Feb 16, 2021	BUY	$17.82 - $31.73 $522,126 - $929,689	29,300 New	29,300 $824,000

Others Institutions Holding ARQT

# of Institutions

197

Shares Held

129M

Call Options Held

738K

Put Options Held

82K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $861M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account